New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 13, 2012
09:00 EDTTKMRTekmira Pharmaceuticals rises 36.7%
Tekmira Pharmaceuticals is up 36.7%, or $1.88, to $7.00
News For TKMR From The Last 14 Days
Check below for free stories on TKMR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent TKMR news | >>
August 13, 2014
17:09 EDTTKMRTekmira down 7% following Q2 results, corporate update
17:04 EDTTKMRTekmira slips in extended session trade, levels to watch
Subscribe for More Information
16:40 EDTTKMRTekmira to resume trading at 5:00pm ET
Subscribe for More Information
16:38 EDTTKMRTekmira sees filing IND, Equiv for TKM-HBV in 2H14
The company said the following: "The single ascending dose portion of the TKM-Ebola Phase I clinical trial has been successfully completed in healthy human volunteers. As per the protocol maximum tolerated dose was established to be 0.3 mg/kg for healthy subjects without steroid premedication. In July, we received notice from the U.S. Food & Drug Administration that our TKM-Ebola program was on clinical hold. Subsequently, the company received written notice from the FDA modifying the clinical hold to a "partial clinical hold," allowing for the potential use of TKM-Ebola in individuals who have a confirmed or suspected Ebola infection. The company remains on clinical hold as it relates to the multiple-ascending dose portion of the Phase I clinical study in healthy volunteers with TKM-Ebola. The company expects this matter to be resolved by Q4 2014. Our therapeutic, TKM-Ebola, is currently an unapproved agent and the regulatory framework to support its use in Africa has not yet been established. Given the severity of the situation, we are carefully evaluating options for use of our investigational drug within accepted clinical and regulatory protocols. This includes discussions with government agencies and NGO's, including the WHO, in various countries on the potential use of TKM-Ebola to treat Ebola virus infected individuals. There can be no assurance that an appropriate framework for the use of this product will be found. We will continue to provide updates as necessary when clinical and regulatory pathways become confirmed. Within our TKM-PLK1 clinical trial targeting GI-NET and ACC patients, we saw an additional RECIST qualifying Partial Response, defined as a greater than 30 percent reduction in target tumor lesions. This patient is continuing on therapy and has achieved a 44 percent reduction in their target tumor mass, located outside of the liver. Furthermore, scans of the target tumor lesions demonstrate signs of necrosis, indicative of anti-tumor activity. We have initiated a Phase I/II clinical study of TKM-PLK1 in patients with Hepatocellular Carcinoma. We intend to file an Investigational New Drug application, or equivalent, in the second half of 2014, in order to advance our TKM-HBV program into a Phase I clinical study, with initial data available in 2015."
16:34 EDTTKMRTekmira provides operational update
Subscribe for More Information
16:33 EDTTKMRTekmira reports Q2 EPS (28c), consensus (26c)
Reports Q2 revenue $1.8M, consensus $3.69M.
16:25 EDTTKMRTekmira trading halted, pending news
Subscribe for More Information
August 12, 2014
07:15 EDTTKMRWHO says ethical to offer unproven interventions in light of Ebola outbreak
Subscribe for More Information
06:03 EDTTKMRTekmira implied volatility of 145 at upper end of index mean range
Subscribe for More Information
August 11, 2014
11:04 EDTTKMRActive equity options trading on open
Subscribe for More Information
10:49 EDTTKMRTekmira volatility elevated on wide price movement
Subscribe for More Information
10:14 EDTTKMRTekmira extends its recent rally, levels to watch
Subscribe for More Information
05:54 EDTTKMRStocks with implied volatility movement; COH TKMR
Subscribe for More Information
August 8, 2014
16:28 EDTTKMROn The Fly: Closing Wrap
Stocks began the session in positive territory despite President Obama authorizing air strikes against the Islamic State militant group in northern Iraq in conjunction with a humanitarian effort. The early move higher stalled but the market then moved higher as reports confirmed that Russian military aircraft exercises near the Ukraine border had ended, as planned. ECONOMIC EVENTS: In the U.S., productivity growth rose 2.5% in the second quarter, beating expectations for a rise of 1.6%. Second quarter unit labor costs, however, only increased 0.6%, which was below the 1% consensus forecast. Wholesale inventories increased 0.3% in June, and sales were up 0.2%, which were both below expectations. COMPANY NEWS: Shares of McDonald's (MCD) were fractionally higher despite the company reporting that its comparable store sales fell 2.5% in July, which was significantly worse than expected. The fast food giant stated that its U.S. comparable sales were down 3.2% in the month compared to the same month of last year and that comp sales in Asia/Pacific, Middle East and Africa dropped 7.3%. The APMEA region's comparable sales decline reflects the impact of food quality and safety issues at a supplier to McDonald's and other food companies in China which caused a "significant negative impact" to results in China, Japan and certain other markets, the company noted. As a result of the China supplier issue, the company's previously issued global comparable sales forecast for 2014 is now at risk, McDonald's added. MAJOR MOVERS: Among the notable gainers was chip maker NVIDIA (NVDA), which rose $1.54, or 8.82%, to $19.00 after the company’s second quarter profit and third quarter revenue outlook surpassed analysts’ consensus estimates. Also higher was small-cap Tekmira Pharmaceuticals (TKMR), which jumped $6.43, or 45.06%, to $20.70 after announcing that the FDA has verbally confirmed they have modified the full clinical hold placed on the TKM-Ebola Investigational New Drug Application to a partial clinical hold. Among the noteworthy losers was cereal maker Post Holdings (POST), which fell $7.08, or 15.91%, to $37.43 and was downgraded to Neutral from Buy at SunTrust after the company reported an adjusted net loss for its third quarter and agreed to acquire American Blanching Company for $128M. Also lower were shares of Ignite Restaurant (IRG), the owner of the Joe’s Crab Shack and Macaroni Grill brands, which fell $4.33, or 34.98%, to $8.05 after reporting second quarter results that missed analysts' expectations and having its shares downgraded at Raymond James and CL King. INDEXES: The Dow advanced 185.66, or 1.13%, to 16,553.93, the Nasdaq gained 35.93, or 0.83%, to 4,370.90, and the S&P 500 rose 22.02, or 1.15%, to 1,931.59.
10:16 EDTTKMRHigh option volume stocks
09:55 EDTTKMRTekmira rallies sharply, levels to watch
Subscribe for More Information
09:15 EDTTKMROn The Fly: Pre-market Movers
HIGHER: NVIDIA (NVDA), up 4.2%, upgraded at Needham following its better than expected Q2 results... Arista Networks (ANET), up 8%, upgraded at Citigroup following better than expected Q2 results, announcing an expanded strategic relationship with VMware (VMW)... Tekmira Pharmaceuticals (TKMR), up 17.5% after announcing that the FDA verbally confirmed they have modified the full clinical hold placed on its TKM-Ebola treatment to a partial clinical hold... Gap (GPS), up 4.7% after July same-store sales rose 2%, company issues Q2 EPS outlook above the consensus estimate... lululemon (LULU), up 2.4% after founder agrees to sell half his stake to Advent for $845M. UP AFTER EARNINGS: SolarCity (SCTY), up 1%... Assured Guaranty (AGO), up 9%... MercadoLibre (MELI), up 13.6%. LOWER: Zynga (ZNGA), down 6% after lowering fiscal 2014 guidance... McDonald's (MCD), down 0.4% after Chinese supplier issue contributes to July comparable sales drop of 2.5%.
08:24 EDTTKMRTekmira Ebola drug could see emergency use in U.S., says Maxim
Subscribe for More Information
07:41 EDTTKMRTekmira Ebola drug could be used in Africa, U.S., says RBC Capital
Subscribe for More Information
07:33 EDTTKMRTekmira volatility expected to move on FDA modification of TKM-Ebola
Tekmira volatility is expected to move after announcing that the FDA verbally confirmed they have modified the full clinical hold placed on the TKM-Ebola to a partial clinical hold. August call option implied volatility is at 133, September is at 110, December is at 94, March is at 98; compared to its 15-week average of 99 according to Track Data, suggesting large near term price movement.
1 | 2 | all recent TKMR news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use